GHK-Cu / BPC-157 / TB-500 research blend
Glow
Research blend of GHK-Cu (50 mg) + BPC-157 (10 mg) + TB-500 (10 mg) supplied as a lyophilized single-vial preparation, 70 mg total peptide mass
Overview
Glow is a research blend, not a peptide. It combines three components — GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg) — in a single lyophilized vial for 70 mg total peptide mass. Relative to Aura (see the sibling blend page), Glow substitutes TB-500 for KPV, a change that alters the mechanism story from repair-with-inflammation-control to repair-with-cellular-migration. That single swap is the editorial identity of the blend.
The mechanism composition is coherent. Tissue repair happens across several rate-limiting layers: gene-level ECM signalling, vascular supply, cellular migration, and inflammatory-environment control. Glow addresses three of these four (gene expression, vascular supply, cellular migration) rather than the three Aura addresses (gene expression, vascular supply, inflammation control). The GHK-Cu component drives broad ECM gene modulation; the BPC-157 component drives VEGF angiogenesis and fibroblast recruitment; the TB-500 component regulates actin polymerisation dynamics that enable stem cells and repair cells to migrate to injury sites. All three components have peer-reviewed evidence at the individual level (see the component pages); none of the three has been evaluated as part of this specific combination in a randomised trial.
The dose profile at the reference reconstitution and 0.2 mL injection is worth understanding honestly. Reconstituting the 70 mg vial with 5.0 mL of bacteriostatic water gives GHK-Cu 10 mg/mL, BPC-157 2 mg/mL and TB-500 2 mg/mL. An 0.2 mL injection delivers GHK-Cu 2.0 mg + BPC-157 0.4 mg + TB-500 0.4 mg. For GHK-Cu and BPC-157, the per-injection doses fall within their individually-established therapeutic ranges. For TB-500, 0.4 mg × 5 injections per week = 2 mg per week — this is maintenance-level dosing, not acute-injury loading. The TB-500 label case for full loading is 2.5 mg × 2 injections per week for the first two weeks (i.e. 5 mg/week during the load). Anyone using Glow for an acute musculoskeletal injury who needs the full TB-500 loading effect should either supplement with additional TB-500 during the loading phase or select a formulation that dosed it higher.
The evidence position is the same as it is for Aura and every other multi-component blend: component-level evidence is real (see the component pages for the peer-reviewed detail) but does not automatically constitute evidence for the specific combination. No randomised placebo-controlled trial has evaluated GHK-Cu + BPC-157 + TB-500 as a single product. The blend inherits the biology of its components; consumers should not import clinical validation from component papers to combination claims.
Quick Facts & Evidence
- Category
- GHK-Cu / BPC-157 / TB-500 research blend
- Research area
- Research blend
- Most studied for
- Skin rejuvenation and dermatological repair
- General tissue repair with a cellular-migration component
- Chronic recovery and resilience support
- Post-injury maintenance (rather than acute loading)
- Clinical status
- Research use only — no approved clinical indication
- Human evidence
- Preclinical Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Preclinical Evidence
Data are from animal models, cell studies, or anecdotal community reports. No controlled human evidence.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format (three-component repair blend)
This page covers the RUO lyophilized Glow blend vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. Glow shares Aura's mass architecture (70 mg total, 50/10/10 mass split) but substitutes TB-500 for KPV — trading upstream NF-κB suppression for cytoskeletal cell migration.
Glow research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 70 mg total (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg) |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 5.0 mL |
| Final concentration (mixed) | GHK-Cu 10 mg/mL; BPC-157 2 mg/mL; TB-500 2 mg/mL |
| How it's given | Subcutaneous injection |
| Research dose (20 units = 0.2 mL) | GHK-Cu 2.0 mg + BPC-157 0.4 mg + TB-500 0.4 mg per injection |
| Injections per vial | 25 (5-week supply at 5× per week) |
| Frequency | 5× per week |
| Cycling | 3 months on / 1 month off |
Reported Dosing
The practitioner-reference research protocol for Glow is a single 20-unit (0.2 mL) subcutaneous injection five times per week, run in 3-month cycles with a 1-month washout. That shot delivers GHK-Cu 2.0 mg + BPC-157 0.4 mg + TB-500 0.4 mg. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 20 units (0.2 mL): GHK-Cu 2.0 mg + BPC-157 0.4 mg + TB-500 0.4 mg | 5× per week, subcutaneous | 3 months on / 1 month off | One 70 mg vial = 25 injections = 5-week supply |
Why protocols vary
The three ingredients target complementary repair layers — GHK-Cu drives ECM gene modulation and collagen/elastin stimulation; BPC-157 drives VEGF angiogenesis and fibroblast recruitment; TB-500 adds cytoskeletal cell migration through actin polymerisation regulation. For skin health and maintenance recovery Glow delivers all three within useful ranges.
For acute musculoskeletal injury where full TB-500 loading (5–10 mg per week) is needed, the practitioner reference is explicit that a standalone TB-500 vial should be run in parallel — Glow's per-injection TB-500 dose (0.4 mg) is at maintenance level, not loading level.
The 3-month-on / 1-month-off cadence prevents receptor-system adaptation across long-term multi-target repair signalling.
Preparing the Solution
Turning the freeze-dried blend into a measurable liquid.
Blend composition
70 mg total peptide (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg)
The vial holds three lyophilized peptides in the same cake. Reconstituting with 5.0 mL bacteriostatic water dissolves all three at once. Because the ingredients are unevenly weighted, the per-ingredient concentrations differ (GHK-Cu at 10 mg/mL, BPC-157 and TB-500 at 2 mg/mL each). A single 0.2 mL injection delivers GHK-Cu 2.0 mg + BPC-157 0.4 mg + TB-500 0.4 mg.
GHK-Cu
- Mass in vial
- 50 mg
- Share of total
- 71.4%
- Concentration after mixing
- 10 mg/mL
- Reported per-injection dose
- 2.0 mg per injection
BPC-157
- Mass in vial
- 10 mg
- Share of total
- 14.3%
- Concentration after mixing
- 2 mg/mL
- Reported per-injection dose
- 0.4 mg per injection
TB-500
- Mass in vial
- 10 mg
- Share of total
- 14.3%
- Concentration after mixing
- 2 mg/mL
- Reported per-injection dose
- 0.4 mg per injection (maintenance level, not loading)
One reconstitution, one injection volume — all three ingredients arrive together in parallel. TB-500 at 0.4 mg per injection is a maintenance-level dose; acute musculoskeletal injury loading (5–10 mg TB-500 per week) is documented separately on the TB-500 page and typically requires a standalone TB-500 vial in parallel.
Documented in the practitioner reference (chapter 31)
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 70 mg blend vial (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg)
Diluent: 5.0 mL bacteriostatic water
Final concentration: 14 mg/mL total (GHK-Cu 10 + BPC 2 + TB 2 mg/mL)
Vial and volume from the practitioner reference; per-ingredient concentrations calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
5mL
Resulting concentration
14 mg/mL
Equivalent volume
The reported research amount of 2.8 mg is contained within
0.2mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 70 mg ÷ 5 mL = 14 mg/mL
- Bacteriostatic water to match the documented concentration
- 70 mg ÷ 14 mg/mL = 5 mL
- Equivalent volume at this concentration
- 2.8 mg ÷ 14 mg/mL = 0.2 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner reference (total-blend arithmetic; per-ingredient split shown above; 20-unit injection = 0.2 mL = 2.8 mg total)Research-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO blend preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, 5× per week
Documented in the practitioner reference · Research-practitioner guide
Why this method
All three ingredients are peptides that would be degraded by gastrointestinal proteolysis; the subcutaneous route delivers them into circulation intact.
Systemic subcutaneous dosing is used because the mechanism relies on tissue-wide signalling (ECM gene regulation, angiogenesis, cell-migration cytoskeletal signalling) rather than a localised depot.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Back of the upper arm
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light — copper is photosensitive
- Do not freeze
General RUO practice; GHK-Cu photosensitivity · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within the 5-week vial supply window
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice; supply-window per practitioner reference · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling. TB-500 (the 17-amino-acid fragment used in this blend) is separately WADA-prohibited in athletes; blend use inherits this restriction.
Common Cycle
The practitioner reference frames Glow as 3-month active cycles followed by a 1-month washout.
- Cycle Length
- 3 months on per cycle
- Break Before the Next Cycle
- 1-month washout between cycles
- What the Research Shows
- No blend-specific long-term trial exists; individual-component pharmacology characterised in Pickart 2018 (GHK-Cu genome-wide review), Seiwerth 2019 / Chang 2011 (BPC-157), and Goldstein 1972 (thymosin β4 parent-protein origin)
Documented in the practitioner reference; individual-component literature · Research-practitioner guide
All three ingredients are pro-angiogenic and the blend is contraindicated in active cancer; Wilson's disease and copper metabolism disorders are additional contraindications because of the GHK-Cu component.
Compound Overview
Current areas of research
Component-level effects and grey-market blend experience. No blend-specific trial evidence.
- Skin rejuvenation and collagen support (GHK-Cu, build over 4–12 weeks)
- Vascular repair and fibroblast recruitment (BPC-157)
- Cellular migration and cytoskeletal remodelling (TB-500)
- General maintenance recovery support
Mechanism of action
Glow is a research blend, not a peptide. It combines three components — GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg) — in a single lyophilized vial for 70 mg total peptide mass. Relative to Aura (see the sibling blend page), Glow substitutes TB-500 for KPV, a change that alters the mechanism story from repair-with-inflammation-control to repair-with-cellular-migration. That single swap is the editorial identity of the blend.
The mechanism composition is coherent. Tissue repair happens across several rate-limiting layers: gene-level ECM signalling, vascular supply, cellular migration, and inflammatory-environment control. Glow addresses three of these four (gene expression, vascular supply, cellular migration) rather than the three Aura addresses (gene expression, vascular supply, inflammation control). The GHK-Cu component drives broad ECM gene modulation; the BPC-157 component drives VEGF angiogenesis and fibroblast recruitment; the TB-500 component regulates actin polymerisation dynamics that enable stem cells and repair cells to migrate to injury sites. All three components have peer-reviewed evidence at the individual level (see the component pages); none of the three has been evaluated as part of this specific combination in a randomised trial.
The dose profile at the reference reconstitution and 0.2 mL injection is worth understanding honestly. Reconstituting the 70 mg vial with 5.0 mL of bacteriostatic water gives GHK-Cu 10 mg/mL, BPC-157 2 mg/mL and TB-500 2 mg/mL. An 0.2 mL injection delivers GHK-Cu 2.0 mg + BPC-157 0.4 mg + TB-500 0.4 mg. For GHK-Cu and BPC-157, the per-injection doses fall within their individually-established therapeutic ranges. For TB-500, 0.4 mg × 5 injections per week = 2 mg per week — this is maintenance-level dosing, not acute-injury loading. The TB-500 label case for full loading is 2.5 mg × 2 injections per week for the first two weeks (i.e. 5 mg/week during the load). Anyone using Glow for an acute musculoskeletal injury who needs the full TB-500 loading effect should either supplement with additional TB-500 during the loading phase or select a formulation that dosed it higher.
The evidence position is the same as it is for Aura and every other multi-component blend: component-level evidence is real (see the component pages for the peer-reviewed detail) but does not automatically constitute evidence for the specific combination. No randomised placebo-controlled trial has evaluated GHK-Cu + BPC-157 + TB-500 as a single product. The blend inherits the biology of its components; consumers should not import clinical validation from component papers to combination claims.
- Three-component repair blend with skin-rejuvenation emphasis: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg = 70 mg total
- Substitutes TB-500 (cellular migration) for KPV (inflammation control) relative to Aura
- TB-500 at 0.4 mg per injection × 5 injections/week is maintenance-level rather than acute-injury loading
Human research
No blend-specific research literature exists for Glow. The relevant evidence lives at the component level: GHK-Cu (Pickart 2018), BPC-157 (Seiwerth 2019, Chang 2011 tendon repair), TB-500 (thymosin β4 development literature from the Goldstein tradition).
The blend inherits component-level biology; combination-specific validation would require a specific trial that has not been conducted.
Pickart 2018 GHK-Cu review
Framework for the GHK-Cu component. See the GHK-Cu page for the full context.
Seiwerth 2019 BPC-157 review
Framework for the BPC-157 component.
Goldstein 1972 (thymosin discovery)
Foundational discovery of the thymosin family that includes TB-500's parent molecule.
Chang 2011 BPC-157 tendon
Representative BPC-157 tendon-repair preclinical evidence.
Glow is a research blend without any combination-product regulatory authorisation. Each component has its own regulatory profile (see the component pages).
No randomised placebo-controlled trial of Glow as a blend exists.
BPC-157 is on the WADA prohibited list under S0 — this applies to any BPC-157-containing blend including Glow.
Safety considerations
Component-level and grey-market experience.
- Mild injection-site reactions
- Mild bruising from copper component
- Component-level side effects apply
- Long-term safety of the specific three-way combination not characterised
All component-level warnings apply.
- Active or recent malignancy — all three components pro-angiogenic
- Wilson's disease / copper disorders — GHK-Cu component
- Pregnancy and breastfeeding
- Hypersensitivity to any component
- BPC-157 WADA prohibited-list considerations apply
Monitoring
- Injection-site reactions
- Pigmented lesion changes (theoretical concern with copper)
- Systemic tolerability
Frequently asked questions
Is Glow the same as Aura?
No. Aura is GHK-Cu + BPC-157 + KPV; Glow is GHK-Cu + BPC-157 + TB-500. Both are three-component repair blends with the same 70 mg total mass, but they address different mechanistic layers: Aura adds inflammation control (KPV), Glow adds cellular migration (TB-500). Klow adds both.
Is Glow good for acute musculoskeletal injury?
At the reference dose, no — the TB-500 component is at maintenance rather than acute-loading levels. Acute TB-500 loading typically requires 2.5 mg × 2 injections per week for the first two weeks (5 mg/week during the load). Glow's 0.2 mL injection delivers 0.4 mg of TB-500, and at 5 injections per week that is 2 mg/week — less than half the acute loading dose. Anyone using Glow for acute injury who needs the full TB-500 loading effect should supplement with additional TB-500 during the loading phase.
Why is TB-500 underdosed at the reference injection?
It is a mathematical consequence of the 5:1:1 ratio used to keep GHK-Cu at a therapeutically meaningful dose per injection. If TB-500 were increased, either the vial mass would need to increase substantially or the GHK-Cu dose per injection would fall below its useful range. The trade-off is honest, and it is the reason Glow is more of a maintenance-repair and skin-rejuvenation blend than an acute-injury blend.
Does Glow require the same warnings as Aura?
Yes for the GHK-Cu and BPC-157 components (active malignancy, Wilson's disease, pregnancy, WADA S0 for BPC-157). Glow does not carry the KPV-specific considerations because it lacks the KPV component. It adds the TB-500 immune / vascular considerations.
How does Glow compare to using individual peptides?
Glow's advantage is convenience — one reconstitution, one injection delivers all three components. Its disadvantage is dose flexibility — the ratios are fixed, so you cannot titrate TB-500 up for acute loading without adding supplemental TB-500. For chronic maintenance and skin rejuvenation, the convenience often outweighs the flexibility loss. For acute contexts requiring full TB-500 loading, individual peptides give more control.
References
- [1]
GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration — a consolidating review — Pickart L, Vasquez-Soltero JM, Margolina A, BioMed Research International / consolidating review (2018)
- [2]
BPC 157 and Standard Angiogenic Growth Factors — Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Seiwerth S, Milavic M, Vukojevic J, et al., Frontiers in Pharmacology (2019)
- [3]
Isolation of a biologically active fraction from bovine thymus (thymosin fraction 5) — the discovery paper for the thymosin peptide family — Goldstein AL, Guha A, Zatz MM, Hardy MA, White A, Proceedings of the National Academy of Sciences (1972)
- [4]
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS, Journal of Applied Physiology (2011)
- [5]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.